Literature DB >> 18215784

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.

Parameswaran Hari1, Jeanette Carreras, Mei-Jie Zhang, Robert Peter Gale, Brian J Bolwell, Christopher N Bredeson, Linda J Burns, Mitchell S Cairo, César O Freytes, Steven C Goldstein, Gregory A Hale, David J Inwards, Charles F Lemaistre, Dipnarine Maharaj, David I Marks, Harry C Schouten, Shimon Slavin, Julie M Vose, Hillard M Lazarus, Koen van Besien.   

Abstract

Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem cell transplantation (HSCT) in follicular lymphoma (FL). We compared traditional myeloablative conditioning regimens to RIC in FL. Outcomes of HLA-identical sibling HSCT for FL in 208 recipients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1997 and 2002 were studied. Conditioning regimens were categorized as myeloablative (N = 120) or RIC (N = 88). Use of RIC regimens increased from <10% of transplants in 1997 to >80% in 2002 signaling a major shift in practice. Patients receiving RIC were older and had a longer interval from diagnosis to transplant. These differences did not correlate with outcomes. Median follow-up of survivors was 50 months (4-96 months) after myeloablative conditioning versus 35 months (4-82 months) after RIC (P < .001). At 3 years, overall survival (OS) for the myeloablative and RIC cohorts were 71 (63%-79%) and 62 (51%-72%; P = .15) and progression free survival (PFS), 67 (58%-75%) and 55 (44%-65%; P = .07), respectively. Lower Karnofsky performance score (KPS) and resistance to chemotherapy were associated with higher treatment-related mortality (TRM) and lower OS and PFS. On multivariate analysis, an increased risk of lymphoma progression after RIC was observed (relative risk = 2.97, P = .04). RIC has become the de facto standard in allogeneic HSCT for FL, and appears to result in similar long-term outcomes. Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215784      PMCID: PMC2531158          DOI: 10.1016/j.bbmt.2007.11.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

Review 1.  Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling.

Authors:  J P Klein; J D Rizzo; M J Zhang; N Keiding
Journal:  Bone Marrow Transplant       Date:  2001-12       Impact factor: 5.483

2.  Confidence bands for the difference of two survival curves under proportional hazards model.

Authors:  M J Zhang; J P Klein
Journal:  Lifetime Data Anal       Date:  2001-09       Impact factor: 1.588

3.  Nonmyeloablative stem cell transplantation for lymphoma.

Authors:  Issa F Khouri; Richard E Champlin
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

4.  Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.

Authors:  Charles Crawley; Simona Iacobelli; Bo Björkstrand; Jane F Apperley; Dietger Niederwieser; Gösta Gahrton
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

Review 5.  Non-myeloablative transplants for malignant disease.

Authors:  R F Storb; R Champlin; S R Riddell; M Murata; S Bryant; E H Warren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

6.  Quantification of the completeness of follow-up.

Authors:  Taane G Clark; Douglas G Altman; Bianca L De Stavola
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

Authors:  Roberto Rodriguez; Auayporn Nademanee; Nora Ruel; Eileen Smith; Amrita Krishnan; Leslie Popplewell; Jasmine Zain; Kathy Patane; Neil Kogut; Ryotaro Nakamura; Clarence Sarkodee-Adoo; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

8.  A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.

Authors:  Daniel Anderson; Todd DeFor; Linda Burns; Philip McGlave; Jeffrey Miller; John Wagner; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-01       Impact factor: 5.742

9.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Authors:  Mohamed L Sorror; Michael B Maris; Barry Storer; Brenda M Sandmaier; Razvan Diaconescu; Christopher Flowers; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

10.  Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

Authors:  Emma Morris; Kirsty Thomson; Charles Craddock; Prem Mahendra; Donald Milligan; Gordon Cook; Graeme Murray Smith; Anne Parker; Steve Schey; Rajesh Chopra; Christopher Hatton; Jane Tighe; Anne Hunter; Karl Peggs; David Linch; Anthony Goldstone; Stephen Mackinnon
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  50 in total

1.  Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

Authors:  Koen van Besien; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Lucy A Godley; Peter H O'Donnell; Justin Kline; Vu Nguyen; Paula Del Cerro; Richard A Larson; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-09       Impact factor: 5.742

2.  Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Authors:  Wichai Chinratanalab; Nishitha Reddy; John P Greer; David Morgan; Brian Engelhardt; Adetola Kassim; Stephen J Brandt; Madan Jagasia; Stacey Goodman; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

Review 3.  Cutaneous graft-versus-host disease--clinical considerations and management.

Authors:  Peggy A Wu; Edward W Cowen
Journal:  Curr Probl Dermatol       Date:  2012-02-17

Review 4.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

Review 6.  Role of hematopoietic stem cell transplant in the management of follicular lymphoma.

Authors:  Matthew Foster; Don A Gabriel; Thomas Shea
Journal:  Oncologist       Date:  2009-06-26

7.  Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.

Authors:  Mehdi Hamadani; Michael Craig; Gary S Phillips; Jame Abraham; William Tse; Aaron Cumpston; Laura Gibson; Scot C Remick; Pamela Bunner; Sonia Leadmon; Patrick Elder; Craig Hofmeister; Sam Penza; Yvonne Efebera; Leslie Andritsos; Ramiro Garzon; Don M Benson; William Blum; Steven M Devine
Journal:  Hematol Oncol       Date:  2011-02-28       Impact factor: 5.271

8.  Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Authors:  Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Ginna G Laport; Silvia Montoto; David G Maloney; Hillard M Lazarus
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-01       Impact factor: 5.742

9.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

10.  Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.

Authors:  Nishitha M Reddy; Olalekan Oluwole; John P Greer; Brian G Engelhardt; Madan H Jagasia; Bipin N Savani
Journal:  Exp Hematol       Date:  2013-10-02       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.